Literature DB >> 19575492

Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.

Mohannad Abu-Hilal1, Jayant Tawaker.   

Abstract

AIM: To describe the clinical presentation and complications of portal hypertension (PH) secondary to myelofibrosis with myeloid metaplasia (MMM).
METHODS: Medical records for 123 patients with MMM were reviewed.
RESULTS: Thirteen patients with PH secondary to MMM were identified. Median ages at time of MMM and PH diagnosis were 61 and 66 years, respectively. The interval from MMM diagnosis to presentation with one of the PH features ranged from 1 to 11 years. Variceal bleeding and ascites were the most common presentations. Of the eight patients who presented with variceal bleeding, six patients underwent endoscopic variceal ligation (EVL) with no variceal recurrence or hematological worsening during a 12-mo follow up period.
CONCLUSION: Patients with MMM might develop PH. Exact mechanisms leading to PH in MMM are still controversial. As in other etiologies, variceal bleeding and ascites are the most common presentations. Anemia may correlate with, and/or predict, the severity of the PH presentation in these patients. EVL can successfully control variceal bleeding in MMM. Further clinical studies are required.

Entities:  

Mesh:

Year:  2009        PMID: 19575492      PMCID: PMC2705735          DOI: 10.3748/wjg.15.3128

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Re: Transjugular intrahepatic portosystemic shunt for intractable esophageal-gastric variceal hemorrhage in a patient with idiopathic myelofibrosis.

Authors:  N Tanaka; K Yamakado; H Kihira; A Hashimoto; T Murayama; K Takeda
Journal:  Cardiovasc Intervent Radiol       Date:  2000 Nov-Dec       Impact factor: 2.740

2.  Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis.

Authors:  W C Lee; H C Lin; S H Tsay; Y Y Yang; M C Hou; F Y Lee; F Y Chang; S D Lee
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

3.  Endoscopic rubber band ligation for bleeding oesophageal varices in portal hypertension due to idiopathic myelofibrosis.

Authors:  Gheorghe Ghidirim; Ion Corchmaru; Igor Mishin; Alexander Danch; Gheorghe Zastavnitsky
Journal:  J Gastrointestin Liver Dis       Date:  2006-09       Impact factor: 2.008

4.  Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

Authors:  A Tefferi; R A Mesa; D M Nagorney; G Schroeder; M N Silverstein
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

5.  Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  J Bĕlohlávek; J Schwarz; A Jirásek; A Krajina; F Polák; M Hrubý
Journal:  Wien Klin Wochenschr       Date:  2001-03-15       Impact factor: 1.704

6.  TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy.

Authors:  Antonia Perelló; Juan Carlos García-Pagán; Rosa Gilabert; Yanette Suárez; Eduardo Moitinho; Francisco Cervantes; Juan Carlos Reverter; Angels Escorsell; Jaume Bosch; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

Review 7.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

8.  Endoscopic variceal ligation for portal hypertension due to myelofibrosis with myeloid metaplasia.

Authors:  Nikolaos Nikolaidis; Olga Giouleme; Maria Sileli; Konstantinos Tziomalos; Nikolaos Grammatikos; Vassilia Garipidou; Nikolaos Eugenidis
Journal:  Eur J Haematol       Date:  2004-05       Impact factor: 2.997

9.  A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation.

Authors:  R Wiest; U Strauch; H Wagner; M Strotzer; M Woenckhaus; G Schröder; J Schölmerich; G Lock
Journal:  Scand J Gastroenterol       Date:  2004-04       Impact factor: 2.423

10.  Acute variceal bleed in a patient with idiopathic myelofibrosis successfully treated with endoscopic variceal band ligation.

Authors:  Brian K P Goh; Juliana J C Chen; Hiang-Khoon Tan; Wei-Sean Yong; Weng-Hoong Chan
Journal:  Dig Dis Sci       Date:  2007-01       Impact factor: 3.487

View more
  13 in total

1.  Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.

Authors:  Matthew Yan; Holly Geyer; Ruben Mesa; Ehab Atallah; Jeannie Callum; Justyna Bartoszko; Karen Yee; Manjula Maganti; Florence Wong; Vikas Gupta
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-11

2.  Hyperinsulinemia and insulin resistance in a patient with type 2 diabetes complicated with myelofibrosis.

Authors:  Hidetaka Hamasaki; Shuichi Mishima; Hidekatsu Yanai
Journal:  World J Diabetes       Date:  2012-08-15

3.  Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis.

Authors:  Xiu-Qing Wei; Zong-Heng Zheng; Yi Jin; Jin Tao; Kodjo-Kunale Abassa; Zhuo-Fu Wen; Chun-Kui Shao; Hong-Bo Wei; Bin Wu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

4.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23

5.  Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.

Authors:  Fabio P S Santos; Constantine S Tam; Hagop Kantarjian; Jorge Cortes; Deborah Thomas; Raphael Pollock; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-05-15

6.  Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

Authors:  Ankur Varma; Susan C Abraham; Rohtesh S Mehta; Neeraj Y Saini; Medhavi Honhar; Munazza Rashid; Julianne Chen; Samer A Srour; Qaiser Bashir; Gabriela Rondon; Betul Oran; Chitra M Hosing; Yago Nieto; Partow Kebriaei; Amin M Alousi; Sairah Ahmed; David Marin; Issa F Khouri; Stefan O Ciurea; Muzaffar H Qazilbash; Katy Rezvani; Paolo Anderlini; Borje S Andersson; Elizabeth J Shpall; Richard E Champlin; Uday R Popat
Journal:  Blood Adv       Date:  2020-04-14

7.  Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.

Authors:  Ken Ogasawara; William B Smith; Christine Xu; Jian Yin; Maria Palmisano; Gopal Krishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-24       Impact factor: 3.333

8.  Portal hypertension and myeloproliferative neoplasms: a relationship revealed.

Authors:  Ahmet Burak Toros; Serkan Gokcay; Guven Cetin; Muhlis Cem Ar; Yesim Karagoz; Besir Kesici
Journal:  ISRN Hematol       Date:  2013-09-16

9.  Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.

Authors:  Debanjali Mitra; James A Kaye; Lance T Piecoro; Jennifer Brown; Kelly Reith; Tariq I Mughal; Nicholas J Sarlis
Journal:  Cancer Med       Date:  2013-10-05       Impact factor: 4.452

Review 10.  Practical management of patients with myelofibrosis receiving ruxolitinib.

Authors:  Claire Harrison; Ruben Mesa; David Ross; Adam Mead; Clodagh Keohane; Jason Gotlib; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.